Literature DB >> 7559886

Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes.

T Okabe1, M Haji, R Takayanagi, M Adachi, K Imasaki, F Kurimoto, T Watanabe, H Nawata.   

Abstract

Although evidence indicates that dehydroepiandrosterone (DHEA) exerts direct physiological effects, its mechanism of action remains unknown. DHEA binding sites were examined using a whole-cell binding assay in a human T lymphoid cell line, PEER, revealing that a single class of high-affinity binding sites for DHEA (dissociation constant = 7.4 +/- 0.53 nmol/L, mean +/- SE, n = 4) was greatly increased when treated with DHEA, phorbol-12-myristate-13-acetate, and the Ca2+ ionophore A23187. Bound [3H]DHEA was displaced sensitively by DHEA and secondarily by dihydrotestosterone, but not effectively by other steroids, including DHEA sulfate. These results not only indicate the existence of a DHEA receptor, but also suggest that T cells become susceptible to regulation by DHEA during the process of signal-induced activation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559886     DOI: 10.1210/jcem.80.10.7559886

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Nipple Aspirate Fluid Hormone Concentrations and Breast Cancer Risk.

Authors:  Robert T Chatterton; Richard E Heinz; Angela J Fought; David Ivancic; Claire Shappell; Subhashini Allu; Susan Gapstur; Denise M Scholtens; Peter H Gann; Seema A Khan
Journal:  Horm Cancer       Date:  2016-02-22       Impact factor: 3.869

2.  Endocrine mechanisms of stress-induced DHEA-secretion.

Authors:  R Oberbeck; R J Benschop; R Jacobs; W Hosch; J U Jetschmann; T H Schürmeyer; R E Schmidt; M Schedlowski
Journal:  J Endocrinol Invest       Date:  1998-03       Impact factor: 4.256

3.  Prevention of immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection.

Authors:  Z Zhang; M Araghi-Niknam; B Liang; P Inserra; S K Ardestani; S Jiang; S Chow; R R Watson
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

Review 4.  Asthma and dehydroepiandrosterone (DHEA): facts and hypotheses.

Authors:  Alicja Kasperska-Zajac
Journal:  Inflammation       Date:  2010-10       Impact factor: 4.092

5.  Dehydroepiandrosterone in systemic lupus erythematosus.

Authors:  Amr H Sawalha; Susan Kovats
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

Review 6.  Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects.

Authors:  Sylvie Legrain; Laurence Girard
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Differential regulation of dehydroepiandrosterone and estrogen on bone and uterus in ovariectomized mice.

Authors:  L Wang; Y-D Wang; W-J Wang; D-J Li
Journal:  Osteoporos Int       Date:  2008-08-09       Impact factor: 4.507

8.  Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats.

Authors:  Rui-Sheng Duan; Hans Link; Bao-Guo Xiao
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

Review 9.  Might DHEA be considered a beneficial replacement therapy in the elderly?

Authors:  Alessandro D Genazzani; Chiara Lanzoni; Andrea R Genazzani
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  Effects of dehydroepiandrosterone on Th2 cytokine production in peripheral blood mononuclear cells from asthmatics.

Authors:  Inseon S Choi; Yong Cui; Young Ah Koh; Hyun Chul Lee; Yong Bum Cho; Young Ho Won
Journal:  Korean J Intern Med       Date:  2008-12       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.